Industry Verticals »

All Categories

Insights »

About TMR »

Antiviral Combination Therapies Market

Antiviral Combination Therapies Market (Drug Combination: NRTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, and Others; Type: Branded and Generic; Indication: HIV, Hepatitis, and Others; Route of Administration: Oral and Intravenous; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Multiple Antiviral Drugs Prove More Effective in Treatment of COVID-19 than Single Drugs

The triple combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b holds promising potentials in the treatment of coronavirus (COVID-19). Researchers in healthcare companies and organizations are referring historical findings of the lopinavir-ritonavir & ribavirin combination, which was effective in lowering the morbidity and mortality rate of the then SARS (Severe Acute Respiratory Syndrome). Since COVID-19 is a novel viral infection, companies in the antiviral combination therapies market are increasing their research in triple combination therapies to advance in the coronavirus treatment.

Many Coronavirus patients are in need for intensive respiratory support in hospitals. Since lopinavir–ritonavir and interferon beta-1b were found to reduce the viral load in SARS, companies in the antiviral combination therapies market are increasing focus in these drugs to innovate in antiviral drugs for coronavirus. It has been found that multiple antiviral drugs help to improve patient outcomes as compared to the consumption of single drug treatments.

Strategic Collaborations Help Increase Combination Therapy Trials for Combating Coronavirus

Companies in the antiviral combination therapies market are taking giant strides by increasing their trails to combat COVID-19. The Indian Institute of Chemical Technology (IICT) has joined forces with the Indian subsidiary of global pharmaceutical company, Mylan, to innovate in combination therapies for coronavirus. Many pharmaceutical companies in India have entered the Phase 3 of clinical trials with the help of computational modelling of molecules and laboratory-based data. The unprecedented demand for antiviral drugs has fueled innovations in combination therapy trials. Moreover, rising COVID-19 cases in India is acting as a key driver for market growth.

Medical institutes are increasing efforts to collaborate with hospitals to innovate in combination therapy trials. It has been found that the combination of antiviral drugs with antibiotics holds promising potentials in minimizing coronavirus symptoms in patients.

Traditional Chinese Medicine with Entecavir Reduces Morbidity in Hepatitis B Patients

The antiviral combination therapies market is projected to advance at a high CAGR during the assessment period. Healthcare companies are exploring new therapy avenues such as the combined therapy of traditional Chinese medicine (TCM), along with antiviral drugs for the treatment of chronic hepatitis B (CHB). The Chinese YinQiSanHuang-antiviral decoction with entecavir is gaining popularity for reducing the annual incidence of liver fibrosis/cirrhosis amongst hepatitis B patients. Thus, analysts of Transparency Market Research (TMR) anticipate that the antiviral combination therapy is a fast growing phenomenon for hepatitis B treatment.

It has been found that conventional antiviral drugs alone are not enough for the efficacious hepatitis B treatment. As such, there is a need for credible clinical evidence to understand the combination of TCM and Western medicines for the hepatitis B treatment.
 

Small Molecule Antagonists Combined with Oral Antivirals for Hepatitis Treatment

The combination therapy with lamivudine or tenofovir and pegylated interferon (PEG-IFN) has been reported for the treatment of hepatitis B. As such, there is a need for clarification on clinical evidence to analyze the long-term efficacy of this type of combination therapy for CHB. Hepatitis B patients with low hepatitis B surface antigen (HBsAg) levels are being recommended with the combination therapy. However, the scientific community is faced with challenges such as restrictions in research project funds, which breaks the long-term continuity of trial periods. Hence, companies in the antiviral combination therapies market should increase their research expenditure to explore new combination therapies based on different mechanisms.

New drug developments are in pipeline for companies in the antiviral combination therapies market. In November 2018, Gilead Sciences— the U.S. biopharmaceutical company, announced that combination of GS-9688— an investigational oral selective small molecule agonist and oral antivirals is well tolerated among viral hepatitis patients.

New ARV Regimens Minimize Incidence of Intolerable Adverse Effects in HIV Patients

North America is predicted to account for the lion’s share in revenue of the antiviral combination therapies market during 2020-2030. However, adults living with HIV (Human Immunodeficiency Virus) have been reported to encounter adverse effects such as metabolic complications and kidney dysfunction due to the adoption of the combination antiretroviral therapy (ART). Hence, healthcare companies are increasing their R&D efforts to develop new ARV regimens that cause fewer serious and intolerable adverse effects than regimens used in the past.

NRTIs (Nucleoside Reverse Transcriptase Inhibitors) are associated with multiple mechanisms of action among HIV patients. Companies in the antiviral combination therapies market such as Merck are keen on development of their Islatravir NRTI. Manufacturers are increasing the availability of NRTIs that have greater inhibitory quotients against drug-resistant mutations. Such manufacturers have a competitive edge in the market since traditional NRTIs confer low fold-shifts in potency.
PEG IFN and Nucleoside Analogues Combination Enhances Immune Response in CHB Patients

Chronic hepatitis B is found to be an important cause for cirrhosis and hepatocellular carcinoma (HCC) worldwide. In order to avoid incidence of HCC, companies in the antiviral combination therapies market are increasing the availability of nucleoside analogues or pegylated interferon in order to prevent progression to cirrhosis. As such, antiviral combination therapy is being highly publicized as an additive and a synergistic agent to prevent HCC in hepatitis B patients. Hence, companies in the antiviral combination therapies market are increasing research to identify the sequence of treatments that can be efficacious in minimizing HCC in CHB patients.

Combinations of nucleoside analogues and PEG IFN bode well for preventing progression of cirrhosis in hepatitis B patients. Healthcare companies are capitalizing on incremental opportunities, since PEG IFN and nucleoside analogues result in lowering hepatitis B surface antigen (HBsAg) concentrations and enhancing immune response.

Analysts’ Viewpoint

Anti-HIV combination drugs are gaining popularity for fighting COVID-19. Combination strategies involving PEG IFN and nucleoside analogues help to inhibit hepatitis B virus replication in patients, whilst enhancing immune response. Investigational small molecule agonists are being used with oral antivirals to advance in clinical trials for viral hepatitis.

Traditional Chinese medicine in combination with entecavir holds promising potentials for the hepatitis B treatment. However, antiviral medicines such as tenofovir or lamivudine are not recommended during the treatment. Hence, companies in the antiviral combination therapies market should increase awareness about the adverse effects of drugs to avoid morbidity and mortality in hepatitis B patients.

Antiviral Combination Therapies Market: Overview

  • The global antiviral combination therapies market was valued at US$ 40.4 Bn in 2019 and is projected to expand at a high CAGR from 2020 to 2030. Antiviral combination therapies are drugs developed using a combination of two or more drugs for the treatment of various viral diseases, including chronic hepatitis B, hepatitis C, and HIV. Combination antiretroviral therapy aids in stopping the virus from making multiple copies of itself in the body.
  • The global antiviral combination therapies market is driven by significant growth in spending on research & development by market players for the development of effective antiviral combination therapies for the treatment of a range of viral diseases; ability of the combination therapy to control the antibiotic resistance, and increase in focus on drug repurposing and vaccine development for the treatment of COVID-19.

Antiviral Combination Therapies Market: Segmentation

  • The global antiviral combination therapies market has been segmented based on drug combination, type, indication, route of administration, distribution channel, and region
  • In terms of drug combination, the global antiviral combination therapies market has been categorized into NRTI/NNRTI, integrase inhibitor/NRTI, NRTI, NRTI/protease inhibitor, and others. Based on type, the global antiviral combination therapies market has been divided into branded and generic.
  • In terms of indication, the global antiviral combination therapies market has been classified into HIV, hepatitis, and others. Globally, in 2019, over 38 million people lived with HIV. Of these, around 36.2 million were adults and 1.8 million were children. Additionally, over 1.7 million individuals acquired HIV in 2019. Based on route of administration, the global antiviral combination therapies market has been bifurcated into oral and intravenous.
  • In terms of distribution channel, the global antiviral combination therapies market has been segregated into hospital pharmacies, retail pharmacies, and others

Antiviral Combination Therapies Market: Regional Segmentation

  • In terms of region, the global antiviral combination therapies market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global antiviral combination therapies market in 2019 and the trend is projected to continue during the forecast period
  • The antiviral combination therapies market in Asia Pacific is anticipated to expand at a high CAGR from 2020 to 2030. Growth of the antiviral combination therapies market in the region can be attributed to high prevalence rate of HCV and HIV, and increase in market penetration of generic drug manufacturers. Additionally, large pool of patients suffering from chronic diseases in countries such as China and India and wide retail pharmacy network contribute to the growth of the antiviral combination therapies market in Asia Pacific.

Antiviral Combination Therapies Market: Major Players

  • The global antiviral combination therapies market is fragmented in terms of number of players. Key players operating in the global antiviral combination therapies market are
    • Celltrion, Inc.
    • GlaxoSmithKline plc
    • Gilead Sciences, Inc.
    • AbbVie, Inc.
    • Bristol-Myers Squibb Company
    • Janssen Global Services
    • LLC (Pharmaceutical Companies of Johnson & Johnson)
    • Cipla, Inc.
    • Mylan N.V.
    • Merck & Co., Inc.
    •  F. Hoffmann-La Roche Ltd.
    • among others.
  • In August 2020, Janssen Global Services entered into an agreement with the U.S. Government for the large-scale development and manufacturing of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the U.S., following the approval of Emergency Use Authorization by the U.S. Food and Drug Administration (FDA)
  • In May 2020, Gilead received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Veklury (remdesivir), for the treatment of COVID-19 in Japanese patients

Frequently Asked Questions

What is the total market worth of antiviral combination therapies market?

Antiviral combination therapies market to reach valuation of US$ 71.4 Bn by 2030

What are the key driving factors for the growth of the antiviral combination therapies market?

Antiviral combination therapies market is driven by increase in investment in R&D for the development of combination medications that aid in fighting antiviral resistance

Which is the rising prominent segment in the antiviral combination therapies market?

The integrase inhibitor/NRTI segment is projected to account for a major share of the global antiviral combination therapies market during the forecast period

Which region is expected to project the highest market share in the global antiviral combination therapies market?

North America accounted for a major share of the global antiviral combination therapies market in terms of revenue in 2019 and the trend is anticipated to continue during the forecast period

Who are the key players in the global antiviral combination therapies market?

Key players in the global antiviral combination therapies market include Celltrion, Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., AbbVie, Inc., Bristol-Myers Squibb Company

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Antiviral Combination Therapies Market

    4. Market Overview

        4.1. Definition

        4.2. Market Indicators

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, 2018–2030

        4.5. Global Antiviral Combination Therapies Market Outlook

    5. Key Insights

        5.1. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

        5.2. Major Selling Antiviral Combination Drugs

        5.3. Patent Information of Combination Therapies

        5.4. Pipeline Analysis

        5.5. Key Industry Events

        5.6. Disease Epidemiology

    6. Global Antiviral Combination Therapies Market Analysis and Forecast, by Drug Combination

        6.1. Introduction

        6.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination

        6.3. Global Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

            6.3.1. NRTI/NNRTI

            6.3.2. Integrase Inhibitor/NRTI

            6.3.3. NRTI

            6.3.4. NRTI/Protease Inhibitor

            6.3.5. Others

        6.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination

    7. Global Antiviral Combination Therapies Market Analysis and Forecast, by Type

        7.1. Introduction

        7.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Type

        7.3. Global Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

            7.3.1. Branded

            7.3.2. Generic

        7.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Type

    8. Global Antiviral Combination Therapies Market Analysis and Forecast, by Indication

        8.1. Introduction

        8.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Indication

        8.3. Global Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

            8.3.1. HIV

            8.3.2. Hepatitis

            8.3.3. Others

        8.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Indication

    9. Global Antiviral Combination Therapies Market Analysis and Forecast, by Route of Administration

        9.1. Introduction

        9.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration

        9.3. Global Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

            9.3.1. Oral

            9.3.2. Intravenous

        9.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration

    10. Global Antiviral Combination Therapies Market Analysis and Forecast, by Distribution Channel

        10.1. Introduction

        10.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel

        10.3. Global Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

            10.3.1. Hospital Pharmacies

            10.3.2. Retail Pharmacies

            10.3.3. Others

        10.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel

    11. Global Antiviral Combination Therapies Market Analysis and Forecast, by Region

        11.1. Regional Outlook

        11.2. Introduction

        11.3. Global Antiviral Combination Therapies Market Value Forecast, by Region

            11.3.1. North America

            11.3.2. Europe

            11.3.3. Asia Pacific

            11.3.4. Latin America

            11.3.5. Middle East & Africa

        11.4.  Global Antiviral Combination Therapies Market Attractiveness Analysis, by Region

    12. North America Antiviral Combination Therapies Market Analysis and Forecast

        12.1.  Key Findings

        12.2.  North America Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

            12.2.1. NRTI/NNRTI

            12.2.2. Integrase Inhibitor/NRTI

            12.2.3. NRTI

            12.2.4. NRTI/Protease Inhibitor

            12.2.5. Others

        12.3. North America Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

            12.3.1. Branded

            12.3.2. Generic

        12.4. North America Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

            12.4.1. HIV

            12.4.2. Hepatitis

            12.4.3. Others

        12.5. North America Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

            12.5.1. Oral

            12.5.2. Intravenous

        12.6. North America Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

            12.6.1. Hospital Pharmacies

            12.6.2. Retail Pharmacies

            12.6.3. Others

        12.7. North America Antiviral Combination Therapies Market Value Forecast, by Country, 2018–2030

            12.7.1. U.S.

            12.7.2. Canada

        12.8. North America Antiviral Combination Therapies Attractiveness Analysis

            12.8.1. By Drug Combination

            12.8.2. By Type

            12.8.3. By Indication

            12.8.4. By Route of Administration

            12.8.5. By Distribution Channel

            12.8.6. By Country

    13. Europe Antiviral Combination Therapies Market Analysis and Forecast

        13.1.  Key Findings

        13.2.  Europe Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

            13.2.1. NRTI/NNRTI

            13.2.2. Integrase Inhibitor/NRTI

            13.2.3. NRTI

            13.2.4. NRTI/Protease Inhibitor

            13.2.5. Others

        13.3. Europe Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

            13.3.1. Branded

            13.3.2. Generic

        13.4. Europe Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

            13.4.1. HIV

            13.4.2. Hepatitis

            13.4.3. Others

        13.5. Europe Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

            13.5.1. Oral

            13.5.2. Intravenous

        13.6. Europe Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

            13.6.1. Hospital Pharmacies

            13.6.2. Retail Pharmacies

            13.6.3. Others

        13.7. Europe Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030

            13.7.1. U.K.

            13.7.2. Germany

            13.7.3. France

            13.7.4. Italy

            13.7.5. Spain

            13.7.6. Rest of Europe

        13.8. Europe Antiviral Combination Therapies Market Attractiveness Analysis

            13.8.1. By Drug Combination

            13.8.2. By Type

            13.8.3. By Indication

            13.8.4. By Route of Administration

            13.8.5. By Distribution Channel

            13.8.6. By Country/Sub-region

    14. Asia Pacific Antiviral Combination Therapies Market Analysis and Forecast

        14.1.  Key Findings

        14.2. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

            14.2.1. NRTI/NNRTI

            14.2.2. Integrase Inhibitor/NRTI

            14.2.3. NRTI

            14.2.4. NRTI/Protease Inhibitor

            14.2.5. Others

        14.3. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

            14.3.1. Branded

            14.3.2. Generic

        14.4. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

            14.4.1. HIV

            14.4.2. Hepatitis

            14.4.3. Others

        14.5. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

            14.5.1. Oral

            14.5.2. Intravenous

        14.6. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

            14.6.1. Hospital Pharmacies

            14.6.2. Retail Pharmacies

            14.6.3. Others

        14.7. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030

            14.7.1. China

            14.7.2. India

            14.7.3. Japan

            14.7.4. Australia & New Zealand

            14.7.5. Rest of Asia Pacific

        14.8. Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis

            14.8.1. By Drug Combination

            14.8.2. By Type

            14.8.3. By Indication

            14.8.4. By Route of Administration

            14.8.5. By Distribution Channel

            14.8.6. By Country/Sub-region

    15. Latin America Antiviral Combination Therapies Market Analysis and Forecast

        15.1.  Key Findings

        15.2. Latin America Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

            15.2.1. NRTI/NNRTI

            15.2.2. Integrase Inhibitor/NRTI

            15.2.3. NRTI

            15.2.4. NRTI/Protease Inhibitor

            15.2.5. Others

        15.3. Latin America Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

            15.3.1. Branded

            15.3.2. Generic

        15.4. Latin America Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

            15.4.1. HIV

            15.4.2. Hepatitis

            15.4.3. Others

        15.5. Latin America Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

            15.5.1. Oral

            15.5.2. Intravenous

        15.6. Latin America Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

            15.6.1. Hospital Pharmacies

            15.6.2. Retail Pharmacies

            15.6.3. Others

        15.7. Latin America Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030

            15.7.1. Brazil

            15.7.2. Mexico

            15.7.3. Rest of Latin America

        15.8. Latin America Antiviral Combination Therapies Market Attractiveness Analysis

            15.8.1. By Drug Combination

            15.8.2. By Type

            15.8.3.  By Indication

            15.8.4. By Route of Administration

            15.8.5. By Distribution Channel

            15.8.6. By Country/Sub-region

    16. Middle East & Africa Antiviral Combination Therapies Market Analysis and Forecast

        16.1.  Key Findings

        16.2. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018–2030

            16.2.1. NRTI/NNRTI

            16.2.2. Integrase Inhibitor/NRTI

            16.2.3. NRTI

            16.2.4. NRTI/Protease Inhibitor

            16.2.5. Others

        16.3. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Type, 2018–2030

            16.3.1. Branded

            16.3.2. Generic

        16.4. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Indication, 2018–2030

            16.4.1. HIV

            16.4.2. Hepatitis

            16.4.3. Others

        16.5. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018–2030

            16.5.1. Oral

            16.5.2. Intravenous

        16.6. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018–2030

            16.6.1. Hospital Pharmacies

            16.6.2. Retail Pharmacies

            16.6.3. Others

        16.7. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018–2030

            16.7.1. GCC Countries

            16.7.2. South Africa

            16.7.3. Rest of Middle East & Africa

        16.8. Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis

            16.8.1. By Drug Combination

            16.8.2. By Type

            16.8.3. By Indication

            16.8.4. By Route of Administration

            16.8.5. By Distribution Channel

            16.8.6. By Country/Sub-region

    17. Competition Landscape

        17.1.  Market Player - Competition Matrix (by tier and size of companies)

        17.2.  Market Share Analysis, by Company, 2019

        17.3. Company Profiles

            17.3.1. Celltrion, Inc.

                17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.1.2. Financial Overview

                17.3.1.3. Product Portfolio

                17.3.1.4. Strategic Overview

                17.3.1.5. SWOT Analysis

            17.3.2. GlaxoSmithKline plc

                17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.2.2. Financial Overview

                17.3.2.3. Product Portfolio

                17.3.2.4. Strategic Overview

                17.3.2.5. SWOT Analysis

            17.3.3. Gilead Sciences, Inc.

                17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.3.2. Financial Overview

                17.3.3.3. Product Portfolio

                17.3.3.4. Strategic Overview

                17.3.3.5. SWOT Analysis

            17.3.4. AbbVie, Inc.

                17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.4.2. Financial Overview

                17.3.4.3. Product Portfolio

                17.3.4.4. Strategic Overview

                17.3.4.5. SWOT Analysis

            17.3.5. Bristol-Myers Squibb Company

                17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.5.2. Financial Overview

                17.3.5.3. Product Portfolio

                17.3.5.4. Strategic Overview

                17.3.5.5. SWOT Analysis

            17.3.6. Janssen Global Services, LLC (Pharmaceutical Companies of Johnson & Johnson)

                17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.6.2. Financial Overview

                17.3.6.3. Product Portfolio

                17.3.6.4. Strategic Overview

                17.3.6.5. SWOT Analysis

            17.3.7. Cipla, Inc.

                17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.7.2. Financial Overview

                17.3.7.3. Product Portfolio

                17.3.7.4. Strategic Overview

                17.3.7.5. SWOT Analysis

            17.3.8. Mylan N.V.

                17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.8.2. Financial Overview

                17.3.8.3. Product Portfolio

                17.3.8.4. Strategic Overview

                17.3.8.5. SWOT Analysis

            17.3.9. Merck & Co., Inc.

                17.3.9.1.  Company Overview (HQ, Business Segments, Employee Strength)

                17.3.9.2. Financial Overview

                17.3.9.3. Product Portfolio

                17.3.9.4. Strategic Overview

                17.3.9.5. SWOT Analysis

            17.3.10. F. Hoffmann-La Roche Ltd.

                17.3.10.1.  Company Overview (HQ, Business Segments, Employee Strength)

                17.3.10.2. Financial Overview

                17.3.10.3. Product Portfolio

                17.3.10.4. Strategic Overview

                17.3.10.5. SWOT Analysis

    List of Tables

    Table 01: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

    Table 02: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

    Table 03: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 04: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 05: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 06: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Region, 2018–2030

    Table 07: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country, 2018–2030

    Table 08: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

    Table 09: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

    Table 10: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 11: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 12: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 13: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 14: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

    Table 15: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

    Table 16: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 17: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 18: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 19: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 20: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

    Table 21: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

    Table 22: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 23: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 24: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 25: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 26: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

    Table 27: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

    Table 28: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 29: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 30: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 31: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 32: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018–2030

    Table 33: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018–2030

    Table 34: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 35: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 36: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    List of Figures

    Figure 01: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, 2018–2030

    Figure 02: Global Antiviral Combination Therapies Market Value Share, by Drug Combination, 2019

    Figure 03: Global Antiviral Combination Therapies Market Value Share, by Type, 2019

    Figure 04: Global Antiviral Combination Therapies Market Value Share, by Indication, 2019

    Figure 05: Global Antiviral Combination Therapies Market Value Share, by Route of Administration, 2019

    Figure 06: Global Antiviral Combination Therapies Market Value Share, by Distribution Channel, 2019

    Figure 07: Global Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030

    Figure 08: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030

    Figure 09: Global Antiviral Combination Therapies Market Value (US$ Mn), by NRTI/NNRTI, 2018–2030

    Figure 10: Global Antiviral Combination Therapies Market Value (US$ Mn), by Integrase Inhibitor/NRTI, 2018–2030

    Figure 11: Global Antiviral Combination Therapies Market Value (US$ Mn), by NRTI, 2018–2030

    Figure 12: Global Antiviral Combination Therapies Market Value (US$ Mn), by NRTI/Protease Inhibitor, 2018–2030

    Figure 13: Global Antiviral Combination Therapies Market Value (US$ Mn), by Others, 2018–2030

    Figure 14: Global Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030

    Figure 15: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030

    Figure 16: Global Antiviral Combination Therapies Market Value (US$ Mn), by Branded, 2018–2030

    Figure 17: Global Antiviral Combination Therapies Market Value (US$ Mn), by Generic, 2018–2030

    Figure 18: Global Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 19: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 20: Global Antiviral Combination Therapies Market Value (US$ Mn), by HIV, 2018–2030

    Figure 21: Global Antiviral Combination Therapies Market Value (US$ Mn), by Hepatitis, 2018–2030

    Figure 22: Global Antiviral Combination Therapies Market Value (US$ Mn), by Others, 2018–2030

    Figure 23: Global Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030

    Figure 24: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030

    Figure 25: Global Antiviral Combination Therapies Market Value (US$ Mn), by Oral, 2018–2030

    Figure 26: Global Antiviral Combination Therapies Market Value (US$ Mn), by Intravenous, 2018–2030

    Figure 27: Global Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 28: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 29: Global Antiviral Combination Therapies Market Value (US$ Mn), by Hospital Pharmacies, 2018–2030

    Figure 30: Global Antiviral Combination Therapies Market Value (US$ Mn), by Retail Pharmacies, 2018–2030

    Figure 31: Global Antiviral Combination Therapies Market Value (US$ Mn), by Others, 2018–2030

    Figure 32: Global Antiviral Combination Therapies Market Value Share Analysis, by Region, 2019 and 2030

    Figure 33: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Region

    Figure 34: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 35: North America Antiviral Combination Therapies Market Value Share Analysis, by Country, 2019 and 2030

    Figure 36: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Country, 2020–2030

    Figure 37: North America Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030

    Figure 38: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030

    Figure 39: North America Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030

    Figure 40: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030

    Figure 41: North America Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 42: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 43: North America Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030

    Figure 44: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030

    Figure 45: North America Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 46: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 47: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 48: Europe Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 49: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 50: Europe Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030

    Figure 51: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030

    Figure 52: Europe Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030

    Figure 53: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030

    Figure 54: Europe Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 55: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 56: Europe Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030

    Figure 57: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030

    Figure 58: Europe Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 59: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 60: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 61: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 62: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 63: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030

    Figure 64: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030

    Figure 65: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030

    Figure 66: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030

    Figure 67: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 68: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 69: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030

    Figure 70: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030

    Figure 71: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 72: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 73: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 74: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 75: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 76: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030

    Figure 77: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030

    Figure 78: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030

    Figure 79: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030

    Figure 80: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 81: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 82: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030

    Figure 83: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030

    Figure 84: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 85: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 86: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 87: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 88: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 89: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030

    Figure 90: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020–2030

    Figure 91: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030

    Figure 92: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020–2030

    Figure 93: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 94: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 95: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030

    Figure 96: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020–2030

    Figure 97: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 98: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 99: Global Antiviral Combination Therapies Market - Company Share Analysis (2019)

Copyright © Transparency Market Research, Inc. All Rights reserved

Antiviral Combination Therapies Market

Schedule a Call